Phase II evaluation of bisantrene in refractory multiple myeloma
Brian G.M. Durie 1 (for the Myeloma Committee of the Southwest Oncology Group study), John Crowley 2, Charles A. Coltman Jr. 3, Robert A. Chapman 4, Stanley P. Balcerzk 5, John D. Bonnet 6, David A. Lipschitz 7, Ronald L. Stephens 8 and Bruce D. Cheson 9 1University of Arizona Cancer Center; 2Southwest Oncology Group Statistical Center-Seattle; 3University of Texas Health Science Center-San Antonio; 4Henry Ford Hospital; 5Ohio State University Health Center; 6Scott & White Clinic; 7University of Arkansas for Medical Science; 8University of Kansas Medical Center; 9University of Utah Medical Center